Greenleaf Trust Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Greenleaf Trust lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,827 shares of the biopharmaceutical company's stock after acquiring an additional 2,279 shares during the period. Greenleaf Trust's holdings in Gilead Sciences were worth $3,230,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. FMR LLC lifted its position in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. Wellington Management Group LLP grew its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after acquiring an additional 749,047 shares in the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp lifted its stake in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares of the company's stock, valued at $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,500 shares of company stock valued at $6,340,745 over the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Stock Down 4.3%

Gilead Sciences stock traded down $4.90 during midday trading on Friday, reaching $109.64. The stock had a trading volume of 6,115,020 shares, compared to its average volume of 7,702,954. Gilead Sciences, Inc. has a 12 month low of $70.21 and a 12 month high of $119.96. The company has a market capitalization of $136.38 billion, a P/E ratio of 23.08, a PEG ratio of 0.71 and a beta of 0.29. The company has a fifty day moving average price of $107.74 and a two-hundred day moving average price of $104.75. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the company posted ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.88%. Gilead Sciences's payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.